Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 3
1951 22
1952 20
1953 18
1954 20
1955 24
1956 14
1957 24
1958 10
1959 7
1960 8
1961 10
1962 18
1963 35
1964 36
1965 38
1966 39
1967 44
1968 60
1969 60
1970 87
1971 91
1972 90
1973 117
1974 143
1975 139
1976 141
1977 115
1978 110
1979 126
1980 111
1981 112
1982 101
1983 114
1984 109
1985 117
1986 113
1987 109
1988 92
1989 111
1990 84
1991 98
1992 106
1993 90
1994 95
1995 73
1996 81
1997 75
1998 75
1999 64
2000 72
2001 68
2002 80
2003 72
2004 85
2005 78
2006 76
2007 85
2008 67
2009 83
2010 65
2011 76
2012 79
2013 88
2014 99
2015 79
2016 78
2017 89
2018 82
2019 78
2020 91
2021 80
2022 86
2023 87
2024 65
2025 92

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,456 results

Results by year

Filters applied: . Clear all
Page 1
Cephalosporin-probenecid drug interactions.
Brown GR. Brown GR. Clin Pharmacokinet. 1993 Apr;24(4):289-300. doi: 10.2165/00003088-199324040-00003. Clin Pharmacokinet. 1993. PMID: 8491057 Review.
The clinical relevance of the changes in cephalosporin distribution associated with probenecid administration has not been investigated. The dose and timing of probenecid administration appear to be major determinants in any possible interaction. Studies with ceftiz …
The clinical relevance of the changes in cephalosporin distribution associated with probenecid administration has not been investigat …
Structural insights into TRPV2 modulation by probenecid.
Rocereta JA, Sturhahn T, Pumroy RA, Fricke TC, Herzog C, Leffler A, Moiseenkova-Bell V. Rocereta JA, et al. Nat Struct Mol Biol. 2025 Jun;32(6):1019-1029. doi: 10.1038/s41594-025-01494-9. Epub 2025 Feb 19. Nat Struct Mol Biol. 2025. PMID: 39972168
The transient receptor potential vanilloid 2 (TRPV2) cation channel is a key player in cardiovascular physiology and pathophysiology. Probenecid (PBC), an FDA-approved uricosuric agent thought to activate TRPV2, has shown promise in enhancing cardiovascular function in bot …
The transient receptor potential vanilloid 2 (TRPV2) cation channel is a key player in cardiovascular physiology and pathophysiology. Pro …
The history and future of probenecid.
Robbins N, Koch SE, Tranter M, Rubinstein J. Robbins N, et al. Cardiovasc Toxicol. 2012 Mar;12(1):1-9. doi: 10.1007/s12012-011-9145-8. Cardiovasc Toxicol. 2012. PMID: 21938493 Review.
Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. ...We review the history of probenecid in this paper and its potential future uses....
Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. ...We revie …
Probenecid-clofibrate interaction.
Veenendaal JR, Brooks PM, Meffin PJ. Veenendaal JR, et al. Clin Pharmacol Ther. 1981 Mar;29(3):351-8. doi: 10.1038/clpt.1981.48. Clin Pharmacol Ther. 1981. PMID: 7471606
Clofibric acid disposition was studied in four healthy men after 1 wk of clofibrate ingestion (500 mg orally every 12 hr) with and without probenecid (500 mg orally every 6 hr). Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage inter …
Clofibric acid disposition was studied in four healthy men after 1 wk of clofibrate ingestion (500 mg orally every 12 hr) with and without …
Clinical pharmacokinetics of probenecid.
Cunningham RF, Israili ZH, Dayton PG. Cunningham RF, et al. Clin Pharmacokinet. 1981 Mar-Apr;6(2):135-51. doi: 10.2165/00003088-198106020-00004. Clin Pharmacokinet. 1981. PMID: 7011657 Review.
A review of the clinical applications and of the disposition of probenecid in man, including drug interactions, is presented. Probenecid is the classical competitive inhibitor of organic acid transport in the kidney and other organs. ...Probenecid and its oxi …
A review of the clinical applications and of the disposition of probenecid in man, including drug interactions, is presented. Prob …
Zidovudine with probenecid.
Duckworth AS, Duckworth GW, Henderson G, Contreras G. Duckworth AS, et al. Lancet. 1990 Aug 18;336(8712):441. doi: 10.1016/0140-6736(90)91988-m. Lancet. 1990. PMID: 1974968 No abstract available.
Naproxen-probenecid interaction.
Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E. Runkel R, et al. Clin Pharmacol Ther. 1978 Dec;24(6):706-13. doi: 10.1002/cpt1978246706. Clin Pharmacol Ther. 1978. PMID: 710028 No abstract available.
Benemid.
MASON RM. MASON RM. Proc R Soc Med. 1956 Aug;49(8):591-4. Proc R Soc Med. 1956. PMID: 13359424 Free article. No abstract available.
[Gout].
OSHIMA Y. OSHIMA Y. Naika. 1962 Dec;10:1101-2. Naika. 1962. PMID: 13940526 Japanese. No abstract available.
Probenecid: an emerging tool for neuroprotection.
Colín-González AL, Santamaría A. Colín-González AL, et al. CNS Neurol Disord Drug Targets. 2013 Nov;12(7):1050-65. doi: 10.2174/18715273113129990090. CNS Neurol Disord Drug Targets. 2013. PMID: 23844693 Review.
Probenecid (PROB) has been widely used for long time for different clinical purposes, from gout treatment to designs as a coadjutant for antibiotic agents. ...
Probenecid (PROB) has been widely used for long time for different clinical purposes, from gout treatment to designs as a coadjutant …
5,456 results